Tag Archives: 2016

Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis

08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.

Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer

19/06/2018 – AB Science expects study to be completed in 2019.

Annual Financial Results as of December 31, 2017

30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.

CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis

19/04/2018 – AB Science will provide additional data through a reexamination procedure